As long as we're sharing alternatives to AMRN for fellow beleaguered shareholders who like to get behind a company they think could do good against debilitating diseases, I've bought a bunch of ATOS, which is supposed to release findings within months of trials of a drug that is aimed at dramatically reducing the damage done by breast cancer and ANVS, which is one of the companies positioning itself to be a player in the Alzheimer's treatment space. What I like about ANVS is that its share float is only about 8 million and it's valued at less than $100 million. It's selling for half of what it was worth three weeks ago. As for ATOS, the company's owner has said he wants to position the company for a sale if the trial results in the next six months live up to expectations.